

Global Tumor Immunotherapy Drugs Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

https://marketpublishers.com/r/GB6F385E9435EN.html

Date: July 2024

Pages: 114

Price: US\$ 3,480.00 (Single User License)

ID: GB6F385E9435EN

Abstracts

According to our (Global Info Research) latest study, the global Tumor Immunotherapy Drugs market size was valued at USD 43830 million in 2022 and is forecast to a readjusted size of USD 77680 million by 2029 with a CAGR of 8.5% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Tumor immunotherapy refers to destroying cancer cells by stimulating and activating the patient's own immune system.

This report is a detailed and comprehensive analysis for global Tumor Immunotherapy Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided. Key Features:

Global Tumor Immunotherapy Drugs market size and forecasts, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2018-2029 Global Tumor Immunotherapy Drugs market size and forecasts by region and country, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2018-2029

Global Tumor Immunotherapy Drugs market size and forecasts, by Type and by Application, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2018-2029

Global Tumor Immunotherapy Drugs market shares of main players, shipments in revenue (\$ Million), sales quantity (K Units), and ASP (US\$/Unit), 2018-2023.



The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries To assess the growth potential for Tumor Immunotherapy Drugs

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace.

This report profiles key players in the global Tumor Immunotherapy Drugs market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bristol Myer Squibb, AstraZeneca, Merck, Roche / Genentech and Ono Pharmaceutical, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence. Market Segmentation

Tumor Immunotherapy Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets. Market segment by Type

lmmı	une Checkpoint Inhibitors
Tumo	or Vaccine
Adop	otive Immunotherapy
Non-	specific Immunomodulator
Market segment by Application	
Hosp	pital
Clinic	
Othe	r

Major players covered



Bristol Myer Squibb	
AstraZeneca	
Merck	
Roche / Genentech	
Ono Pharmaceutical	
Regeneron	
Innovent	
Hengrui Medicine	
Junshi Biosciences	
Pfizer, Inc	
F. Hoffmann-La Roche Ltd	
Incyte Corporation	
NewLink Genetics Corporation	
Celldex Therapeutics, Inc	
GlaxoSmithKline	
Market segment by region, regional analysis covers	
North America (United States, Canada and Mexico)	
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)	
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)	



South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Tumor Immunotherapy Drugs product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Tumor Immunotherapy Drugs, with price, sales, revenue and global market share of Tumor Immunotherapy Drugs from 2018 to 2023.

Chapter 3, the Tumor Immunotherapy Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Tumor Immunotherapy Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Tumor Immunotherapy Drugs market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.

Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.

Chapter 13, the key raw materials and key suppliers, and industry chain of Tumor Immunotherapy Drugs.

Chapter 14 and 15, to describe Tumor Immunotherapy Drugs sales channel, distributors, customers, research findings and conclusion.



Contents

1 MARKET OVERVIEW

- 1.1 Product Overview and Scope of Tumor Immunotherapy Drugs
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
 - 1.3.1 Overview: Global Tumor Immunotherapy Drugs Consumption Value by Type:
- 2018 Versus 2022 Versus 2029
 - 1.3.2 Immune Checkpoint Inhibitors
 - 1.3.3 Tumor Vaccine
 - 1.3.4 Adoptive Immunotherapy
 - 1.3.5 Non-specific Immunomodulator
- 1.4 Market Analysis by Application
 - 1.4.1 Overview: Global Tumor Immunotherapy Drugs Consumption Value by

Application: 2018 Versus 2022 Versus 2029

- 1.4.2 Hospital
- 1.4.3 Clinic
- 1.4.4 Other
- 1.5 Global Tumor Immunotherapy Drugs Market Size & Forecast
- 1.5.1 Global Tumor Immunotherapy Drugs Consumption Value (2018 & 2022 & 2029)
- 1.5.2 Global Tumor Immunotherapy Drugs Sales Quantity (2018-2029)
- 1.5.3 Global Tumor Immunotherapy Drugs Average Price (2018-2029)

2 MANUFACTURERS PROFILES

- 2.1 Bristol Myer Squibb
 - 2.1.1 Bristol Myer Squibb Details
 - 2.1.2 Bristol Myer Squibb Major Business
 - 2.1.3 Bristol Myer Squibb Tumor Immunotherapy Drugs Product and Services
 - 2.1.4 Bristol Myer Squibb Tumor Immunotherapy Drugs Sales Quantity, Average Price,

Revenue, Gross Margin and Market Share (2018-2023)

- 2.1.5 Bristol Myer Squibb Recent Developments/Updates
- 2.2 AstraZeneca
- 2.2.1 AstraZeneca Details
- 2.2.2 AstraZeneca Major Business
- 2.2.3 AstraZeneca Tumor Immunotherapy Drugs Product and Services
- 2.2.4 AstraZeneca Tumor Immunotherapy Drugs Sales Quantity, Average Price,

Revenue, Gross Margin and Market Share (2018-2023)



- 2.2.5 AstraZeneca Recent Developments/Updates
- 2.3 Merck
 - 2.3.1 Merck Details
 - 2.3.2 Merck Major Business
 - 2.3.3 Merck Tumor Immunotherapy Drugs Product and Services
 - 2.3.4 Merck Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue,

Gross Margin and Market Share (2018-2023)

- 2.3.5 Merck Recent Developments/Updates
- 2.4 Roche / Genentech
 - 2.4.1 Roche / Genentech Details
 - 2.4.2 Roche / Genentech Major Business
 - 2.4.3 Roche / Genentech Tumor Immunotherapy Drugs Product and Services
- 2.4.4 Roche / Genentech Tumor Immunotherapy Drugs Sales Quantity, Average Price,

Revenue, Gross Margin and Market Share (2018-2023)

- 2.4.5 Roche / Genentech Recent Developments/Updates
- 2.5 Ono Pharmaceutical
 - 2.5.1 Ono Pharmaceutical Details
 - 2.5.2 Ono Pharmaceutical Major Business
 - 2.5.3 Ono Pharmaceutical Tumor Immunotherapy Drugs Product and Services
 - 2.5.4 Ono Pharmaceutical Tumor Immunotherapy Drugs Sales Quantity, Average

Price, Revenue, Gross Margin and Market Share (2018-2023)

- 2.5.5 Ono Pharmaceutical Recent Developments/Updates
- 2.6 Regeneron
 - 2.6.1 Regeneron Details
 - 2.6.2 Regeneron Major Business
 - 2.6.3 Regeneron Tumor Immunotherapy Drugs Product and Services
 - 2.6.4 Regeneron Tumor Immunotherapy Drugs Sales Quantity, Average Price,

Revenue, Gross Margin and Market Share (2018-2023)

- 2.6.5 Regeneron Recent Developments/Updates
- 2.7 Innovent
 - 2.7.1 Innovent Details
 - 2.7.2 Innovent Major Business
 - 2.7.3 Innovent Tumor Immunotherapy Drugs Product and Services
 - 2.7.4 Innovent Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue,

Gross Margin and Market Share (2018-2023)

- 2.7.5 Innovent Recent Developments/Updates
- 2.8 Hengrui Medicine
 - 2.8.1 Hengrui Medicine Details
 - 2.8.2 Hengrui Medicine Major Business



- 2.8.3 Hengrui Medicine Tumor Immunotherapy Drugs Product and Services
- 2.8.4 Hengrui Medicine Tumor Immunotherapy Drugs Sales Quantity, Average Price,

Revenue, Gross Margin and Market Share (2018-2023)

- 2.8.5 Hengrui Medicine Recent Developments/Updates
- 2.9 Junshi Biosciences
 - 2.9.1 Junshi Biosciences Details
 - 2.9.2 Junshi Biosciences Major Business
 - 2.9.3 Junshi Biosciences Tumor Immunotherapy Drugs Product and Services
- 2.9.4 Junshi Biosciences Tumor Immunotherapy Drugs Sales Quantity, Average Price,

Revenue, Gross Margin and Market Share (2018-2023)

- 2.9.5 Junshi Biosciences Recent Developments/Updates
- 2.10 Pfizer, Inc
 - 2.10.1 Pfizer, Inc Details
 - 2.10.2 Pfizer, Inc Major Business
 - 2.10.3 Pfizer, Inc Tumor Immunotherapy Drugs Product and Services
 - 2.10.4 Pfizer, Inc Tumor Immunotherapy Drugs Sales Quantity, Average Price,

Revenue, Gross Margin and Market Share (2018-2023)

- 2.10.5 Pfizer, Inc Recent Developments/Updates
- 2.11 F. Hoffmann-La Roche Ltd
 - 2.11.1 F. Hoffmann-La Roche Ltd Details
 - 2.11.2 F. Hoffmann-La Roche Ltd Major Business
 - 2.11.3 F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Product and Services
 - 2.11.4 F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Sales Quantity,

Average Price, Revenue, Gross Margin and Market Share (2018-2023)

- 2.11.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
- 2.12 Incyte Corporation
 - 2.12.1 Incyte Corporation Details
 - 2.12.2 Incyte Corporation Major Business
 - 2.12.3 Incyte Corporation Tumor Immunotherapy Drugs Product and Services
 - 2.12.4 Incyte Corporation Tumor Immunotherapy Drugs Sales Quantity, Average

Price, Revenue, Gross Margin and Market Share (2018-2023)

- 2.12.5 Incyte Corporation Recent Developments/Updates
- 2.13 NewLink Genetics Corporation
 - 2.13.1 NewLink Genetics Corporation Details
 - 2.13.2 NewLink Genetics Corporation Major Business
- 2.13.3 NewLink Genetics Corporation Tumor Immunotherapy Drugs Product and Services
- 2.13.4 NewLink Genetics Corporation Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)



- 2.13.5 NewLink Genetics Corporation Recent Developments/Updates
- 2.14 Celldex Therapeutics, Inc.
 - 2.14.1 Celldex Therapeutics, Inc Details
 - 2.14.2 Celldex Therapeutics, Inc Major Business
 - 2.14.3 Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Product and Services
- 2.14.4 Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Sales Quantity,

Average Price, Revenue, Gross Margin and Market Share (2018-2023)

- 2.14.5 Celldex Therapeutics, Inc Recent Developments/Updates
- 2.15 GlaxoSmithKline
 - 2.15.1 GlaxoSmithKline Details
 - 2.15.2 GlaxoSmithKline Major Business
 - 2.15.3 GlaxoSmithKline Tumor Immunotherapy Drugs Product and Services
- 2.15.4 GlaxoSmithKline Tumor Immunotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.15.5 GlaxoSmithKline Recent Developments/Updates

3 COMPETITIVE ENVIRONMENT: TUMOR IMMUNOTHERAPY DRUGS BY MANUFACTURER

- 3.1 Global Tumor Immunotherapy Drugs Sales Quantity by Manufacturer (2018-2023)
- 3.2 Global Tumor Immunotherapy Drugs Revenue by Manufacturer (2018-2023)
- 3.3 Global Tumor Immunotherapy Drugs Average Price by Manufacturer (2018-2023)
- 3.4 Market Share Analysis (2022)
- 3.4.1 Producer Shipments of Tumor Immunotherapy Drugs by Manufacturer Revenue (\$MM) and Market Share (%): 2022
- 3.4.2 Top 3 Tumor Immunotherapy Drugs Manufacturer Market Share in 2022
- 3.4.2 Top 6 Tumor Immunotherapy Drugs Manufacturer Market Share in 2022
- 3.5 Tumor Immunotherapy Drugs Market: Overall Company Footprint Analysis
 - 3.5.1 Tumor Immunotherapy Drugs Market: Region Footprint
 - 3.5.2 Tumor Immunotherapy Drugs Market: Company Product Type Footprint
- 3.5.3 Tumor Immunotherapy Drugs Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 CONSUMPTION ANALYSIS BY REGION

- 4.1 Global Tumor Immunotherapy Drugs Market Size by Region
- 4.1.1 Global Tumor Immunotherapy Drugs Sales Quantity by Region (2018-2029)
- 4.1.2 Global Tumor Immunotherapy Drugs Consumption Value by Region (2018-2029)



- 4.1.3 Global Tumor Immunotherapy Drugs Average Price by Region (2018-2029)
- 4.2 North America Tumor Immunotherapy Drugs Consumption Value (2018-2029)
- 4.3 Europe Tumor Immunotherapy Drugs Consumption Value (2018-2029)
- 4.4 Asia-Pacific Tumor Immunotherapy Drugs Consumption Value (2018-2029)
- 4.5 South America Tumor Immunotherapy Drugs Consumption Value (2018-2029)
- 4.6 Middle East and Africa Tumor Immunotherapy Drugs Consumption Value (2018-2029)

5 MARKET SEGMENT BY TYPE

- 5.1 Global Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2029)
- 5.2 Global Tumor Immunotherapy Drugs Consumption Value by Type (2018-2029)
- 5.3 Global Tumor Immunotherapy Drugs Average Price by Type (2018-2029)

6 MARKET SEGMENT BY APPLICATION

- 6.1 Global Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2029)
- 6.2 Global Tumor Immunotherapy Drugs Consumption Value by Application (2018-2029)
- 6.3 Global Tumor Immunotherapy Drugs Average Price by Application (2018-2029)

7 NORTH AMERICA

- 7.1 North America Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2029)
- 7.2 North America Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2029)
- 7.3 North America Tumor Immunotherapy Drugs Market Size by Country
- 7.3.1 North America Tumor Immunotherapy Drugs Sales Quantity by Country (2018-2029)
- 7.3.2 North America Tumor Immunotherapy Drugs Consumption Value by Country (2018-2029)
 - 7.3.3 United States Market Size and Forecast (2018-2029)
 - 7.3.4 Canada Market Size and Forecast (2018-2029)
- 7.3.5 Mexico Market Size and Forecast (2018-2029)

8 EUROPE

- 8.1 Europe Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2029)
- 8.2 Europe Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2029)



- 8.3 Europe Tumor Immunotherapy Drugs Market Size by Country
 - 8.3.1 Europe Tumor Immunotherapy Drugs Sales Quantity by Country (2018-2029)
- 8.3.2 Europe Tumor Immunotherapy Drugs Consumption Value by Country (2018-2029)
 - 8.3.3 Germany Market Size and Forecast (2018-2029)
 - 8.3.4 France Market Size and Forecast (2018-2029)
 - 8.3.5 United Kingdom Market Size and Forecast (2018-2029)
 - 8.3.6 Russia Market Size and Forecast (2018-2029)
- 8.3.7 Italy Market Size and Forecast (2018-2029)

9 ASIA-PACIFIC

- 9.1 Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2029)
- 9.2 Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2029)
- 9.3 Asia-Pacific Tumor Immunotherapy Drugs Market Size by Region
 - 9.3.1 Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity by Region (2018-2029)
- 9.3.2 Asia-Pacific Tumor Immunotherapy Drugs Consumption Value by Region (2018-2029)
 - 9.3.3 China Market Size and Forecast (2018-2029)
 - 9.3.4 Japan Market Size and Forecast (2018-2029)
 - 9.3.5 Korea Market Size and Forecast (2018-2029)
 - 9.3.6 India Market Size and Forecast (2018-2029)
- 9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
- 9.3.8 Australia Market Size and Forecast (2018-2029)

10 SOUTH AMERICA

- 10.1 South America Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2029)
- 10.2 South America Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2029)
- 10.3 South America Tumor Immunotherapy Drugs Market Size by Country
- 10.3.1 South America Tumor Immunotherapy Drugs Sales Quantity by Country (2018-2029)
- 10.3.2 South America Tumor Immunotherapy Drugs Consumption Value by Country (2018-2029)
 - 10.3.3 Brazil Market Size and Forecast (2018-2029)
 - 10.3.4 Argentina Market Size and Forecast (2018-2029)



11 MIDDLE EAST & AFRICA

- 11.1 Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2029)
- 11.2 Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2029)
- 11.3 Middle East & Africa Tumor Immunotherapy Drugs Market Size by Country
- 11.3.1 Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity by Country (2018-2029)
- 11.3.2 Middle East & Africa Tumor Immunotherapy Drugs Consumption Value by Country (2018-2029)
 - 11.3.3 Turkey Market Size and Forecast (2018-2029)
 - 11.3.4 Egypt Market Size and Forecast (2018-2029)
 - 11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
 - 11.3.6 South Africa Market Size and Forecast (2018-2029)

12 MARKET DYNAMICS

- 12.1 Tumor Immunotherapy Drugs Market Drivers
- 12.2 Tumor Immunotherapy Drugs Market Restraints
- 12.3 Tumor Immunotherapy Drugs Trends Analysis
- 12.4 Porters Five Forces Analysis
 - 12.4.1 Threat of New Entrants
 - 12.4.2 Bargaining Power of Suppliers
 - 12.4.3 Bargaining Power of Buyers
 - 12.4.4 Threat of Substitutes
 - 12.4.5 Competitive Rivalry
- 12.5 Influence of COVID-19 and Russia-Ukraine War
 - 12.5.1 Influence of COVID-19
 - 12.5.2 Influence of Russia-Ukraine War

13 RAW MATERIAL AND INDUSTRY CHAIN

- 13.1 Raw Material of Tumor Immunotherapy Drugs and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Tumor Immunotherapy Drugs
- 13.3 Tumor Immunotherapy Drugs Production Process
- 13.4 Tumor Immunotherapy Drugs Industrial Chain

14 SHIPMENTS BY DISTRIBUTION CHANNEL



- 14.1 Sales Channel
 - 14.1.1 Direct to End-User
 - 14.1.2 Distributors
- 14.2 Tumor Immunotherapy Drugs Typical Distributors
- 14.3 Tumor Immunotherapy Drugs Typical Customers

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

- 16.1 Methodology
- 16.2 Research Process and Data Source
- 16.3 Disclaimer



List Of Tables

LIST OF TABLES

- Table 1. Global Tumor Immunotherapy Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
- Table 2. Global Tumor Immunotherapy Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
- Table 3. Bristol Myer Squibb Basic Information, Manufacturing Base and Competitors
- Table 4. Bristol Myer Squibb Major Business
- Table 5. Bristol Myer Squibb Tumor Immunotherapy Drugs Product and Services
- Table 6. Bristol Myer Squibb Tumor Immunotherapy Drugs Sales Quantity (K Units),
- Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 7. Bristol Myer Squibb Recent Developments/Updates
- Table 8. AstraZeneca Basic Information, Manufacturing Base and Competitors
- Table 9. AstraZeneca Major Business
- Table 10. AstraZeneca Tumor Immunotherapy Drugs Product and Services
- Table 11. AstraZeneca Tumor Immunotherapy Drugs Sales Quantity (K Units), Average
- Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 12. AstraZeneca Recent Developments/Updates
- Table 13. Merck Basic Information, Manufacturing Base and Competitors
- Table 14. Merck Major Business
- Table 15. Merck Tumor Immunotherapy Drugs Product and Services
- Table 16. Merck Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 17. Merck Recent Developments/Updates
- Table 18. Roche / Genentech Basic Information, Manufacturing Base and Competitors
- Table 19. Roche / Genentech Major Business
- Table 20. Roche / Genentech Tumor Immunotherapy Drugs Product and Services
- Table 21. Roche / Genentech Tumor Immunotherapy Drugs Sales Quantity (K Units),
- Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 22. Roche / Genentech Recent Developments/Updates
- Table 23. Ono Pharmaceutical Basic Information, Manufacturing Base and Competitors
- Table 24. Ono Pharmaceutical Major Business
- Table 25. Ono Pharmaceutical Tumor Immunotherapy Drugs Product and Services
- Table 26. Ono Pharmaceutical Tumor Immunotherapy Drugs Sales Quantity (K Units),
- Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share



(2018-2023)

- Table 27. Ono Pharmaceutical Recent Developments/Updates
- Table 28. Regeneron Basic Information, Manufacturing Base and Competitors
- Table 29. Regeneron Major Business
- Table 30. Regeneron Tumor Immunotherapy Drugs Product and Services
- Table 31. Regeneron Tumor Immunotherapy Drugs Sales Quantity (K Units), Average
- Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 32. Regeneron Recent Developments/Updates
- Table 33. Innovent Basic Information, Manufacturing Base and Competitors
- Table 34. Innovent Major Business
- Table 35. Innovent Tumor Immunotherapy Drugs Product and Services
- Table 36. Innovent Tumor Immunotherapy Drugs Sales Quantity (K Units), Average
- Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 37. Innovent Recent Developments/Updates
- Table 38. Hengrui Medicine Basic Information, Manufacturing Base and Competitors
- Table 39. Hengrui Medicine Major Business
- Table 40. Hengrui Medicine Tumor Immunotherapy Drugs Product and Services
- Table 41. Hengrui Medicine Tumor Immunotherapy Drugs Sales Quantity (K Units),
- Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 42. Hengrui Medicine Recent Developments/Updates
- Table 43. Junshi Biosciences Basic Information, Manufacturing Base and Competitors
- Table 44. Junshi Biosciences Major Business
- Table 45. Junshi Biosciences Tumor Immunotherapy Drugs Product and Services
- Table 46. Junshi Biosciences Tumor Immunotherapy Drugs Sales Quantity (K Units),
- Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 47. Junshi Biosciences Recent Developments/Updates
- Table 48. Pfizer, Inc Basic Information, Manufacturing Base and Competitors
- Table 49. Pfizer, Inc Major Business
- Table 50. Pfizer, Inc Tumor Immunotherapy Drugs Product and Services
- Table 51. Pfizer, Inc Tumor Immunotherapy Drugs Sales Quantity (K Units), Average
- Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 52. Pfizer, Inc Recent Developments/Updates
- Table 53. F. Hoffmann-La Roche Ltd Basic Information, Manufacturing Base and Competitors
- Table 54. F. Hoffmann-La Roche Ltd Major Business
- Table 55. F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Product and Services



- Table 56. F. Hoffmann-La Roche Ltd Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 57. F. Hoffmann-La Roche Ltd Recent Developments/Updates
- Table 58. Incyte Corporation Basic Information, Manufacturing Base and Competitors
- Table 59. Incyte Corporation Major Business
- Table 60. Incyte Corporation Tumor Immunotherapy Drugs Product and Services
- Table 61. Incyte Corporation Tumor Immunotherapy Drugs Sales Quantity (K Units),
- Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 62. Incyte Corporation Recent Developments/Updates
- Table 63. NewLink Genetics Corporation Basic Information, Manufacturing Base and Competitors
- Table 64. NewLink Genetics Corporation Major Business
- Table 65. NewLink Genetics Corporation Tumor Immunotherapy Drugs Product and Services
- Table 66. NewLink Genetics Corporation Tumor Immunotherapy Drugs Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 67. NewLink Genetics Corporation Recent Developments/Updates
- Table 68. Celldex Therapeutics, Inc Basic Information, Manufacturing Base and Competitors
- Table 69. Celldex Therapeutics, Inc Major Business
- Table 70. Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Product and Services
- Table 71. Celldex Therapeutics, Inc Tumor Immunotherapy Drugs Sales Quantity (K
- Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 72. Celldex Therapeutics, Inc Recent Developments/Updates
- Table 73. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
- Table 74. GlaxoSmithKline Major Business
- Table 75. GlaxoSmithKline Tumor Immunotherapy Drugs Product and Services
- Table 76. GlaxoSmithKline Tumor Immunotherapy Drugs Sales Quantity (K Units),
- Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 77. GlaxoSmithKline Recent Developments/Updates
- Table 78. Global Tumor Immunotherapy Drugs Sales Quantity by Manufacturer (2018-2023) & (K Units)
- Table 79. Global Tumor Immunotherapy Drugs Revenue by Manufacturer (2018-2023) & (USD Million)



- Table 80. Global Tumor Immunotherapy Drugs Average Price by Manufacturer (2018-2023) & (US\$/Unit)
- Table 81. Market Position of Manufacturers in Tumor Immunotherapy Drugs, (Tier 1,
- Tier 2, and Tier 3), Based on Consumption Value in 2022
- Table 82. Head Office and Tumor Immunotherapy Drugs Production Site of Key Manufacturer
- Table 83. Tumor Immunotherapy Drugs Market: Company Product Type Footprint
- Table 84. Tumor Immunotherapy Drugs Market: Company Product Application Footprint
- Table 85. Tumor Immunotherapy Drugs New Market Entrants and Barriers to Market Entry
- Table 86. Tumor Immunotherapy Drugs Mergers, Acquisition, Agreements, and Collaborations
- Table 87. Global Tumor Immunotherapy Drugs Sales Quantity by Region (2018-2023) & (K Units)
- Table 88. Global Tumor Immunotherapy Drugs Sales Quantity by Region (2024-2029) & (K Units)
- Table 89. Global Tumor Immunotherapy Drugs Consumption Value by Region (2018-2023) & (USD Million)
- Table 90. Global Tumor Immunotherapy Drugs Consumption Value by Region (2024-2029) & (USD Million)
- Table 91. Global Tumor Immunotherapy Drugs Average Price by Region (2018-2023) & (US\$/Unit)
- Table 92. Global Tumor Immunotherapy Drugs Average Price by Region (2024-2029) & (US\$/Unit)
- Table 93. Global Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2023) & (K Units)
- Table 94. Global Tumor Immunotherapy Drugs Sales Quantity by Type (2024-2029) & (K Units)
- Table 95. Global Tumor Immunotherapy Drugs Consumption Value by Type (2018-2023) & (USD Million)
- Table 96. Global Tumor Immunotherapy Drugs Consumption Value by Type (2024-2029) & (USD Million)
- Table 97. Global Tumor Immunotherapy Drugs Average Price by Type (2018-2023) & (US\$/Unit)
- Table 98. Global Tumor Immunotherapy Drugs Average Price by Type (2024-2029) & (US\$/Unit)
- Table 99. Global Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2023) & (K Units)
- Table 100. Global Tumor Immunotherapy Drugs Sales Quantity by Application



(2024-2029) & (K Units)

Table 101. Global Tumor Immunotherapy Drugs Consumption Value by Application (2018-2023) & (USD Million)

Table 102. Global Tumor Immunotherapy Drugs Consumption Value by Application (2024-2029) & (USD Million)

Table 103. Global Tumor Immunotherapy Drugs Average Price by Application (2018-2023) & (US\$/Unit)

Table 104. Global Tumor Immunotherapy Drugs Average Price by Application (2024-2029) & (US\$/Unit)

Table 105. North America Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2023) & (K Units)

Table 106. North America Tumor Immunotherapy Drugs Sales Quantity by Type (2024-2029) & (K Units)

Table 107. North America Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2023) & (K Units)

Table 108. North America Tumor Immunotherapy Drugs Sales Quantity by Application (2024-2029) & (K Units)

Table 109. North America Tumor Immunotherapy Drugs Sales Quantity by Country (2018-2023) & (K Units)

Table 110. North America Tumor Immunotherapy Drugs Sales Quantity by Country (2024-2029) & (K Units)

Table 111. North America Tumor Immunotherapy Drugs Consumption Value by Country (2018-2023) & (USD Million)

Table 112. North America Tumor Immunotherapy Drugs Consumption Value by Country (2024-2029) & (USD Million)

Table 113. Europe Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2023) & (K Units)

Table 114. Europe Tumor Immunotherapy Drugs Sales Quantity by Type (2024-2029) & (K Units)

Table 115. Europe Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2023) & (K Units)

Table 116. Europe Tumor Immunotherapy Drugs Sales Quantity by Application (2024-2029) & (K Units)

Table 117. Europe Tumor Immunotherapy Drugs Sales Quantity by Country (2018-2023) & (K Units)

Table 118. Europe Tumor Immunotherapy Drugs Sales Quantity by Country (2024-2029) & (K Units)

Table 119. Europe Tumor Immunotherapy Drugs Consumption Value by Country (2018-2023) & (USD Million)



Table 120. Europe Tumor Immunotherapy Drugs Consumption Value by Country (2024-2029) & (USD Million)

Table 121. Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2023) & (K Units)

Table 122. Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity by Type (2024-2029) & (K Units)

Table 123. Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2023) & (K Units)

Table 124. Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity by Application (2024-2029) & (K Units)

Table 125. Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity by Region (2018-2023) & (K Units)

Table 126. Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity by Region (2024-2029) & (K Units)

Table 127. Asia-Pacific Tumor Immunotherapy Drugs Consumption Value by Region (2018-2023) & (USD Million)

Table 128. Asia-Pacific Tumor Immunotherapy Drugs Consumption Value by Region (2024-2029) & (USD Million)

Table 129. South America Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2023) & (K Units)

Table 130. South America Tumor Immunotherapy Drugs Sales Quantity by Type (2024-2029) & (K Units)

Table 131. South America Tumor Immunotherapy Drugs Sales Quantity by Application (2018-2023) & (K Units)

Table 132. South America Tumor Immunotherapy Drugs Sales Quantity by Application (2024-2029) & (K Units)

Table 133. South America Tumor Immunotherapy Drugs Sales Quantity by Country (2018-2023) & (K Units)

Table 134. South America Tumor Immunotherapy Drugs Sales Quantity by Country (2024-2029) & (K Units)

Table 135. South America Tumor Immunotherapy Drugs Consumption Value by Country (2018-2023) & (USD Million)

Table 136. South America Tumor Immunotherapy Drugs Consumption Value by Country (2024-2029) & (USD Million)

Table 137. Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity by Type (2018-2023) & (K Units)

Table 138. Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity by Type (2024-2029) & (K Units)

Table 139. Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity by



Application (2018-2023) & (K Units)

Table 140. Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity by Application (2024-2029) & (K Units)

Table 141. Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity by Region (2018-2023) & (K Units)

Table 142. Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity by Region (2024-2029) & (K Units)

Table 143. Middle East & Africa Tumor Immunotherapy Drugs Consumption Value by Region (2018-2023) & (USD Million)

Table 144. Middle East & Africa Tumor Immunotherapy Drugs Consumption Value by Region (2024-2029) & (USD Million)

Table 145. Tumor Immunotherapy Drugs Raw Material

Table 146. Key Manufacturers of Tumor Immunotherapy Drugs Raw Materials

Table 147. Tumor Immunotherapy Drugs Typical Distributors

Table 148. Tumor Immunotherapy Drugs Typical Customers

List of Figures

Figure 1. Tumor Immunotherapy Drugs Picture

Figure 2. Global Tumor Immunotherapy Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Figure 3. Global Tumor Immunotherapy Drugs Consumption Value Market Share by Type in 2022

Figure 4. Immune Checkpoint Inhibitors Examples

Figure 5. Tumor Vaccine Examples

Figure 6. Adoptive Immunotherapy Examples

Figure 7. Non-specific Immunomodulator Examples

Figure 8. Global Tumor Immunotherapy Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029

Figure 9. Global Tumor Immunotherapy Drugs Consumption Value Market Share by Application in 2022

Figure 10. Hospital Examples

Figure 11. Clinic Examples

Figure 12. Other Examples

Figure 13. Global Tumor Immunotherapy Drugs Consumption Value, (USD Million): 2018 & 2022 & 2029

Figure 14. Global Tumor Immunotherapy Drugs Consumption Value and Forecast (2018-2029) & (USD Million)

Figure 15. Global Tumor Immunotherapy Drugs Sales Quantity (2018-2029) & (K Units)

Figure 16. Global Tumor Immunotherapy Drugs Average Price (2018-2029) & (US\$/Unit)



Figure 17. Global Tumor Immunotherapy Drugs Sales Quantity Market Share by Manufacturer in 2022

Figure 18. Global Tumor Immunotherapy Drugs Consumption Value Market Share by Manufacturer in 2022

Figure 19. Producer Shipments of Tumor Immunotherapy Drugs by Manufacturer Sales Quantity (\$MM) and Market Share (%): 2021

Figure 20. Top 3 Tumor Immunotherapy Drugs Manufacturer (Consumption Value) Market Share in 2022

Figure 21. Top 6 Tumor Immunotherapy Drugs Manufacturer (Consumption Value)
Market Share in 2022

Figure 22. Global Tumor Immunotherapy Drugs Sales Quantity Market Share by Region (2018-2029)

Figure 23. Global Tumor Immunotherapy Drugs Consumption Value Market Share by Region (2018-2029)

Figure 24. North America Tumor Immunotherapy Drugs Consumption Value (2018-2029) & (USD Million)

Figure 25. Europe Tumor Immunotherapy Drugs Consumption Value (2018-2029) & (USD Million)

Figure 26. Asia-Pacific Tumor Immunotherapy Drugs Consumption Value (2018-2029) & (USD Million)

Figure 27. South America Tumor Immunotherapy Drugs Consumption Value (2018-2029) & (USD Million)

Figure 28. Middle East & Africa Tumor Immunotherapy Drugs Consumption Value (2018-2029) & (USD Million)

Figure 29. Global Tumor Immunotherapy Drugs Sales Quantity Market Share by Type (2018-2029)

Figure 30. Global Tumor Immunotherapy Drugs Consumption Value Market Share by Type (2018-2029)

Figure 31. Global Tumor Immunotherapy Drugs Average Price by Type (2018-2029) & (US\$/Unit)

Figure 32. Global Tumor Immunotherapy Drugs Sales Quantity Market Share by Application (2018-2029)

Figure 33. Global Tumor Immunotherapy Drugs Consumption Value Market Share by Application (2018-2029)

Figure 34. Global Tumor Immunotherapy Drugs Average Price by Application (2018-2029) & (US\$/Unit)

Figure 35. North America Tumor Immunotherapy Drugs Sales Quantity Market Share by Type (2018-2029)

Figure 36. North America Tumor Immunotherapy Drugs Sales Quantity Market Share by



Application (2018-2029)

Figure 37. North America Tumor Immunotherapy Drugs Sales Quantity Market Share by Country (2018-2029)

Figure 38. North America Tumor Immunotherapy Drugs Consumption Value Market Share by Country (2018-2029)

Figure 39. United States Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 40. Canada Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 41. Mexico Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 42. Europe Tumor Immunotherapy Drugs Sales Quantity Market Share by Type (2018-2029)

Figure 43. Europe Tumor Immunotherapy Drugs Sales Quantity Market Share by Application (2018-2029)

Figure 44. Europe Tumor Immunotherapy Drugs Sales Quantity Market Share by Country (2018-2029)

Figure 45. Europe Tumor Immunotherapy Drugs Consumption Value Market Share by Country (2018-2029)

Figure 46. Germany Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 47. France Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 48. United Kingdom Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 49. Russia Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 50. Italy Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 51. Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity Market Share by Type (2018-2029)

Figure 52. Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity Market Share by Application (2018-2029)

Figure 53. Asia-Pacific Tumor Immunotherapy Drugs Sales Quantity Market Share by Region (2018-2029)

Figure 54. Asia-Pacific Tumor Immunotherapy Drugs Consumption Value Market Share by Region (2018-2029)

Figure 55. China Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)



Figure 56. Japan Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 57. Korea Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 58. India Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 59. Southeast Asia Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 60. Australia Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 61. South America Tumor Immunotherapy Drugs Sales Quantity Market Share by Type (2018-2029)

Figure 62. South America Tumor Immunotherapy Drugs Sales Quantity Market Share by Application (2018-2029)

Figure 63. South America Tumor Immunotherapy Drugs Sales Quantity Market Share by Country (2018-2029)

Figure 64. South America Tumor Immunotherapy Drugs Consumption Value Market Share by Country (2018-2029)

Figure 65. Brazil Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 66. Argentina Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 67. Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity Market Share by Type (2018-2029)

Figure 68. Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity Market Share by Application (2018-2029)

Figure 69. Middle East & Africa Tumor Immunotherapy Drugs Sales Quantity Market Share by Region (2018-2029)

Figure 70. Middle East & Africa Tumor Immunotherapy Drugs Consumption Value Market Share by Region (2018-2029)

Figure 71. Turkey Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 72. Egypt Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 73. Saudi Arabia Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 74. South Africa Tumor Immunotherapy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 75. Tumor Immunotherapy Drugs Market Drivers



Figure 76. Tumor Immunotherapy Drugs Market Restraints

Figure 77. Tumor Immunotherapy Drugs Market Trends

Figure 78. Porters Five Forces Analysis

Figure 79. Manufacturing Cost Structure Analysis of Tumor Immunotherapy Drugs in 2022

Figure 80. Manufacturing Process Analysis of Tumor Immunotherapy Drugs

Figure 81. Tumor Immunotherapy Drugs Industrial Chain

Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors

Figure 83. Direct Channel Pros & Cons

Figure 84. Indirect Channel Pros & Cons

Figure 85. Methodology

Figure 86. Research Process and Data Source



I would like to order

Product name: Global Tumor Immunotherapy Drugs Market 2023 by Manufacturers, Regions, Type and

Application, Forecast to 2029

Product link: https://marketpublishers.com/r/GB6F385E9435EN.html

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GB6F385E9435EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

